Lipitor's Target on HMG-CoA Reductase
Lipitor (atorvastatin) binds primarily to the active site of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This site contains the catalytic residues His237 and Asp690, which coordinate the substrate HMG-CoA and cofactor NADPH. Atorvastatin mimics HMG-CoA's transition state, forming a covalent adduct with Asp690 via its phosphonate group, irreversibly inhibiting the enzyme.[1][2]
How Atorvastatin Binds Compared to Other Statins
Unlike simvastatin or lovastatin, which bind reversibly through non-covalent interactions, atorvastatin's binding is tighter due to this covalent linkage at Asp690. Rosuvastatin shares a similar phosphonate mechanism but has lower affinity at the same site. All statins compete at the HMG-CoA pocket, displacing the natural substrate.[1][3]
Key Residues Involved in Binding
- Asp690: Forms the covalent bond with atorvastatin's C8-hydroxyl (after oxidation).
- His237 and Lys691: Stabilize the HMG-like moiety via hydrogen bonds.
- Gln757 and Ser684: Contribute to the hydrophobic pocket for the atorvastatin fluorophenyl groups.
Crystal structures (e.g., PDB 1HWK) confirm these interactions, with atorvastatin occupying ~85% of the active site volume.[2][4]
Does It Bind Other Sites on the Enzyme?
HMG-CoA reductase has an N-terminal membrane domain and C-terminal catalytic domain; Lipitor targets only the catalytic domain's active site. No significant allosteric binding occurs—efficacy depends on active site occupancy.[1]
Clinical Implications of This Binding
This specificity explains Lipitor's potency (IC50 ~6-10 nM) and long half-life from slow dissociation. Mutations at Asp690 (e.g., in rare resistance cases) abolish binding.[3]
Sources
[1]: DrugPatentWatch.com - Atorvastatin Mechanism
[2]: Istvan ES, Deisenhofer J. Science. 2001;292(5515):1160-4. Structure of HMG-CoA reductase-statins
[3]: Liao H, et al. J Med Chem. 2020;63(5):2447-2461. Statin binding comparisons
[4]: Protein Data Bank. PDB ID: 1HWK. Atorvastatin-HMGCR complex